The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Merck & Co., Inc. (NYSE: MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A close-up of a person’s hand holding a bottle of pharmaceuticals.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Merck said it expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks in the pharma sector. The company has a strong lineup of products in development and brings in solid revenue and earnings. It ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...